Scandinavian Biolabs ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.0% 26.6% 36.1% 24.5% 17.0%  
Credit score (0-100)  0 2 0 2 9  
Credit rating  N/A B C B BB  
Credit limit (kDKK)  0.0 -0.0 -0.0 -0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  0.0 -1,145 -1,883 1,591 5,145  
EBITDA  0.0 -1,775 -4,575 -2,415 -834  
EBIT  0.0 -1,780 -4,589 -2,415 -834  
Pre-tax profit (PTP)  0.0 -1,781.3 -4,612.1 -2,515.8 -1,353.6  
Net earnings  0.0 -1,781.3 -4,612.1 -2,515.8 -1,353.6  
Pre-tax profit without non-rec. items  0.0 -1,781 -4,612 -2,516 -1,354  

 
See the entire income statement

Balance sheet (kDKK) 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 13.9 0.0 0.0 0.0  
Shareholders equity total  0.0 -1,741 -3,415 -5,930 -1,284  
Interest-bearing liabilities  0.0 1,500 1,650 4,930 4,371  
Balance sheet total (assets)  0.0 479 2,545 3,692 11,348  

Net Debt  0.0 1,413 1,506 4,706 488  
 
See the entire balance sheet

Volume 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 -1,145 -1,883 1,591 5,145  
Gross profit growth  0.0% 0.0% -64.4% 0.0% 223.4%  
Employees  0 2 12 19 22  
Employee growth %  0.0% 0.0% 500.0% 58.3% 15.8%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 479 2,545 3,692 11,348  
Balance sheet change%  0.0% 0.0% 431.7% 45.1% 207.4%  
Added value  0.0 -1,775.3 -4,575.3 -2,401.2 -833.9  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 9 -28 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 -1.0 -2.0 -3.0 -4.0  

Profitability 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% 155.4% 243.7% -151.8% -16.2%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% -80.2% -112.1% -29.9% -7.3%  
ROI %  0.0% -118.7% -291.1% -70.7% -17.6%  
ROE %  0.0% -372.2% -305.1% -80.7% -18.0%  

Solidity 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  0.0% -78.4% -57.3% -61.6% -10.2%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% -79.6% -32.9% -194.9% -58.5%  
Gearing %  0.0% -86.1% -48.3% -83.1% -340.5%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.2% 1.7% 5.7% 11.5%  

Liquidity 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  0.0 0.1 0.2 0.2 0.5  
Current Ratio  0.0 0.2 0.4 0.4 0.9  
Cash and cash equivalent  0.0 87.2 144.1 223.8 3,883.1  

Capital use efficiency 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 -1,755.2 -3,464.5 -5,980.4 -1,333.9  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 -888 -381 -126 -38  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 -888 -381 -127 -38  
EBIT / employee  0 -890 -382 -127 -38  
Net earnings / employee  0 -891 -384 -132 -62